- Home
- IBG vs MYNZ Comparison
IBG vs MYNZ Comparison
Compare IBG & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBG
- MYNZ
- Stock Information
- Founded
- IBG 2018
- MYNZ 2021
- Country
- IBG Australia
- MYNZ Germany
- Employees
- IBG N/A
- MYNZ N/A
- Industry
- IBG Beverages (Production/Distribution)
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- IBG Consumer Staples
- MYNZ Health Care
- Exchange
- IBG Nasdaq
- MYNZ Nasdaq
- Market Cap
- IBG 7.8M
- MYNZ 7.9M
- IPO Year
- IBG 2024
- MYNZ 2021
- Fundamental
- Price
- IBG $3.33
- MYNZ $1.68
- Analyst Decision
- IBG Strong Buy
- MYNZ Buy
- Analyst Count
- IBG 1
- MYNZ 2
- Target Price
- IBG N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- IBG 6.0M
- MYNZ 73.5K
- Earning Date
- IBG 11-15-2025
- MYNZ 09-26-2025
- Dividend Yield
- IBG N/A
- MYNZ N/A
- EPS Growth
- IBG N/A
- MYNZ N/A
- EPS
- IBG N/A
- MYNZ N/A
- Revenue
- IBG $2,931,243.00
- MYNZ $659,935.00
- Revenue This Year
- IBG N/A
- MYNZ $26.06
- Revenue Next Year
- IBG N/A
- MYNZ $4.97
- P/E Ratio
- IBG N/A
- MYNZ N/A
- Revenue Growth
- IBG N/A
- MYNZ N/A
- 52 Week Low
- IBG $1.48
- MYNZ $1.30
- 52 Week High
- IBG $11.50
- MYNZ $16.04
- Technical
- Relative Strength Index (RSI)
- IBG 62.66
- MYNZ 54.01
- Support Level
- IBG $2.16
- MYNZ $1.55
- Resistance Level
- IBG $5.38
- MYNZ $1.75
- Average True Range (ATR)
- IBG 0.72
- MYNZ 0.11
- MACD
- IBG 0.10
- MYNZ 0.02
- Stochastic Oscillator
- IBG 48.70
- MYNZ 79.03
About IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 70 formulations across 14 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands. The Group has two reportable geographic segments: Australia and the United States.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.